Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  American Journal of Cardiology

• Publication date

  2000-08-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0002-9149(00)00955-3PMID 10946033
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Estimating

  2018cited by this paper
• Nutrition and coronary heart disease

  2001cited by this paper
• Drug treatment of lipid disorders.

  1999cited by this paper
• Efficacy and safety of Simvastatin 80 mg/day in hypercholesterolemic patients

  1998cited by this paper
• Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome.

  1998cited by this paper
• Management of Dyslipidemia in Adults With Diabetes

  1998cited by this paper
• Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy.

  1998cited by this paper
• Hypertriglyceridemia as a cardiovascular risk factor.

  1998cited by this paper
• Management of dyslipidemia in adults with diabetes. American Diabetes Association.

  1998cited by this paper
• Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group.

  1998cited by this paper
• Comparison of statins in hypertriglyceridemia.

  1998cited by this paper
• Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.

  1997cited by this paper
• The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day.

  1997cited by this paper
• Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

  1996cited by this paper
• Lipids, nutrition, and coronary heart disease.

  1996cited by this paper
• Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial

  1996cited by this paper
• Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia

  1995cited by this paper
• Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

  1993cited by this paper
• The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements.

  1989cited by this paper
• Efficacy and long-term adverse effect pattern of lovastatin.

  1988cited by this paper
• Alcohol and coronary heart disease.

  1984cited by this paper
• Plasma Lipid Distributions in Selected North American Populations: The Lipid Research Clinics Program Prevalence Study THE LIPID RESEARCH CLINICS PROGRAM EPIDEMIOLOGY COMMITTEE

  1979cited by this paper
• A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol.

  1978cited by this paper
• Myocardial infarction in the familial forms of hypertriglyceridemia.

  1976cited by this paper
• Editorial: A System for Phenotyping Hyperlipoproteinemia

  1965cited by this paper
• A SYSTEM FOR PHENOTYPING HYPERLIPOPROTEINEMIA.

  1965cited by this paper

• Influence of physical activity practice on sexual function in men: a systematic review

  2025cites this paper
• Statins—Their Effect on Lipoprotein(a) Levels

  2025cites this paper
• Simvastatin is associated with superior lipid and glycaemic control to atorvastatin and reduced levels of incident Type 2 diabetes, in men and women, in the UK Biobank

  2022cites this paper
• Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis.

  2021cites this paper
• Development and Validation of GC-MS and HPLC Methods for the Determination of Simvastatin in Tablets and Human Urine

  2018cites this paper
• Endothelial Dysfunction and Dyslipidemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy

  2014cites this paper
• Are Statins Reliable Drugs as Mentioned? Indications and Risks for Statins

  2014cites this paper
• Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.

  2013cites this paper
• DIABETIC STUDIES The Review of Atherogenic Dyslipidemia and Combination Pharmacotherapy in Diabetes : Recent Clinical Trials

  2013cites this paper
• Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials

  2013cites this paper
• Pharmacokinetic of simvastatin study in Malaysian subjects

  2013cites this paper
• Meta-analysis on the Role of High-sensitivity C-reactive Protein Monitoring in Relation to the Presence of Glucose Intolerance in Patients Treated with HMG-CoA Reductase Inhibitors

  2012cites this paper
• Increased risk for type 2 diabetes mellitus with HIV-1 infection

  2010cites this paper
• Statins and ischaemia reperfusion injury: a molecular biological review.

  2010cites this paper
• Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia.

  2009cites this paper
• Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.

  2009cites this paper
• Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit

  2008cites this paper
• Clinical Study on the Effect of Simvastatin on Paraoxonase Activity

  2007cites this paper
• The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE Trial Sub-study *

  2006cites this paper
• Statins and bone metabolism.

  2006cites this paper
• The metabolic syndrome: prevalence, CHD risk, and treatment.

  2006cites this paper
• Safety of high-dose atorvastatin therapy.

  2005cites this paper
• Lipid and non-lipid effects of statins.

  2005cites this paper
• Clinical Study on the Effect of Simvastatin on Butyrylcholinesterase Activity

  2005cites this paper
• Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia

  2005cites this paper
• Simvastatin: a review

  2004cites this paper
• Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.

  2004cites this paper
• Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C

  2004cites this paper
• 159 Human Immunodeficiency Virus / Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome : Clinical Presentation , Pathophysiology , and Therapeutic Strategies

  2003cites this paper
• Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).

  2003cites this paper
• Human Immunodeficiency Virus/Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome: Clinical Presentation, Pathophysiology, and Therapeutic Strategies

  2003cites this paper
• Effects of simvastatin, an HMG‐CoA reductase inhibitor, in patients with hypertriglyceridemia

  2003cites this paper
• The Metabolic Syndrome: Targeting Dyslipidaemia to Reduce Coronary Risk

  2003cites this paper
• Clinical review 159: Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies.

  2003cites this paper
• Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.

  2002cites this paper
• Statins: the new aspirin?

  2002cites this paper
• Lipid Modulation and Liver Function Tests: A Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

  2002cites this paper
• Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies.

  2002cites this paper
• High-density lipoprotein cholesterol and the role of statins.

  2002cites this paper
• Lipoprotein changes with statins

  2002cites this paper
• Genetic insights, clinical efficacy and practical implications of genetic screening for familial hypercholesterolemia

  2002cites this paper
• Review Statins: the new aspirin?

  2002cites this paper
• Adrenocorticotrophic hormone exerts marked lipid‐lowering effects in simvastatin‐treated patients

  2001cites this paper
• Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol.

  2001cites this paper
• Current Lipid-lowering Strategies for the Treatment of Diabetic Dyslipidemia: An Integrated Approach to Therapy

  2001cites this paper
• The evolving role of high-density lipoprotein in reducing cardiovascular risk.

  2001cites this paper
• Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S

  2001cites this paper
• Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis.

  2001cites this paper
• Determinants of Variable Response to Statin Treatment in Patients With Refractory Familial Hypercholesterolemia

  2001cites this paper
• Treating mixed dyslipidemias: Why and how

  2001cites this paper
• Therapy and clinical trials.

  2001cites this paper
• Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy.

  2000cites this paper